AegirBio
AegirBio AB has received National Institutes of Health (NIH) programmatic approval for an accessibility project
The company had applied in response to a call for COVID-19 home tests accessible to people with disabilities (https://www.poctrn.org/web/radx-accessible-tests/) with a project based on our emerging saliva testing platform.
"We are excited to receive this approval as this project closely aligns with our vision for easy to use, saliva based testing for Covid-19, other infectious diseases, and biomarker monitoring. The RADx program has a history of supporting impactful, cutting-edge diagnostics and we are honored to be part of that program. I am immensely proud of our team for putting together a compelling proposal and working closely with NIH staff to refine the concept." says Marco Witteveen, CEO AegirBio
This disclosure contains information that AegirBio is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-07-2023 20:32 CET.
| Datum | 2023-07-17, kl 20:32 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!